Exclusive Summary

• First-line standard therapy (WHO Essential Medicine) for over 1.28 billion hypertension patients globally, ensuring massive, chronic, and highly stable market demand.
• Backed by an integrated supply chain (API + FDF), offering significant cost competitiveness ideal for winning government healthcare tenders and penetrating price-sensitive emerging markets.
• Zero patent barriers with ready-to-file ICH CTD dossiers and proven bioequivalence (BE), enabling overseas distributors to achieve fast-track local registration and rapid commercialization.